Loading data for APMD — first visit, this takes a few seconds.
Apnimed, Inc.
26.23 -0.57 (-2.13%)
- Market Cap
- $1.06B
- Volume
- 208K
- Dividend yield
- n/a
- Next earnings date
- Nov 11, 2026
Apnimed, Inc. (APMD) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $84.81M | n/a | n/a |
| EPS | -$0.42 | -$0.08 | n/a |
Metrics
- Bid
- 26.39
- Market Cap
- 1.06B
- Revenue (ttm)
- 115M
- Net Income (ttm)
- 171M
- n/a
- 5.74
- 4.45
- -6.43
- P/B (ttm)
- -0.70
- P/S (ttm)
- 9.24
- Earnings Date
- Nov 11, 2026
- Ask
- 27.19
- Volume
- 207,775
- Avg. Volume (20D)
- 464,380
- Open
- 27.07
- Previous Close
- 26.80
- Day's Range
- 26.18 - 27.72
- 52-Week Range
- 16.12 - 35.29
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Apnimed, Inc.
View profile →Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 2026
Employees 81
Stock Exchange NasdaqGS
Ticker Symbol APMD
Website https://apnimed.com